PEPTIDE THERAPEUTICS MARKET ANALYSIS

Global peptide therapeutics market is estimated to be valued at US$ 44,386.9 million in 2023 and is expected to exhibit a CAGR of 6.6% during the forecast period (2023-2030).

Therapeutic peptides is a unique class of pharmaceutical agents composed of series of amino acids, usually with molecular weights of 500-5000 Da. Since the synthesis of the first therapeutic peptide, insulin, in 1921, remarkable achievements have resulted in the approval of over 80 peptide drugs worldwide. Therefore, peptide drug development has become one of most important topics in pharmaceutical research industry/market.

Analysts’ Views on Global Peptide Therapeutics Market:

Rising research and development activities for various metabolic disorders including cancer is expected to drive the market growth over the forecast period. For instance, in December 2022, the Research team from Technion, a global pioneer in multidisciplinary research, and the University of Tokyo stated that their research study had identified unique peptides with anti-cancer properties. Such peptides with small chains of amino acids plays a potential role in cancer treatment.

Figure 1.Global Peptide Therapeutics Market Share (%), By Product Type, 2023

To learn more about this report, request a free sample copy

Global Peptide Therapeutics Market- Drivers

Increasing research and development activity 

Peptide therapeutics is used in research and development of new drugs and therapies. Thus, increasing research and development activity by key players in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in August 2022, an article published in Biomedicines, an open access journal, stated the use of peptide-based drug development for the development of different treatment options for cancer.

Increasing prevalence of cancer

 Peptide therapeutics technology is used for the treatment of cancer and thus increasing prevalence of cancer is expected to drive the market growth over the forecast period. For instance, in December 2022, according to an article published by National Centre for Biotechnology Information (NCBI), estimated number of incident cases of cancer, in India, for the year 2022 was found to be 14, 61,427. In India, one in nine people are likely to develop cancer in his/her lifetime. Lung and breast cancers were the leading sites of cancer in males and females, respectively.

Figure 2. Global Peptide Therapeutics Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Global Peptide Therapeutics Market- Regional Analysis

Among region, North America is expected to dominate the market over the forecast period, due to increasing adoption of organic growth strategies, such as product approvals by the governing bodies in the region in order to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in September 2022, Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the U.S. Food and Drug Administration (FDA) has approved DAXXIF (DaxibotulinumtoxinA-lanm) injection indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Europe is expected to dominate the market over the forecast period, owing to increasing adoption of inorganic growth strategies, such as acquisition by key players in the region to expand product portfolio, is expected to drive the market growth over the forecast period. For instance, in June 2022, UCB, a multinational biopharmaceutical company, acquired Ra Pharmaceuticals Inc., a clinical-stage Biopharmaceutical Company, to improve the treatment options for people living with myasthenia gravis and other rare diseases.

Global Peptide Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic

Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the World Health Organization (WHO) 44,614,437 people were affected globally, till October 10, 2022.

However, the COVID-19 pandemic had a positive impact on the global peptide therapeutics market, due to increasing research and development activities. For instance, in March 2022, an article published by National Centre for Biotechnology Information (NCBI), stated the use of antimicrobial peptide in the treatment of COVID-19 and it was found that anti-microbial peptides have inhibitory effects on the known proteins of the SARS-CoV-2 virus, and its usage is a promising solution for the treatment of COVID-19.

Global Peptide Therapeutics Market Segmentation:

 Global peptide therapeutics market report is segmented into product type, application, route of administration, and region.

Based on Product Type, the market is segmented into branded peptide and generic peptide. Out of which, branded peptide segment is expected to dominate the peptide therapeutics market during the forecast period, due to increasing product launches by key players in the market

Based on Application, global peptide therapeutics market is segmented into cancer, cardiovascular disease, metabolic disease, respiratory disease, infectious disease, and others. Cancer segment is expected to dominate the market over the forecast period, due to increasing usage of peptide therapeutics to treat cancer.

Based on Route of Administration, global peptide therapeutics market is segmented into oral administration, parenteral administration, and others. Of which, oral administration segment is expected to dominate the market over the forecast period, owing to increasing use of peptide therapeutics technology in treatment of diseases like cancer, diabetes,etc.

Based on Region, the peptide therapeutics market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Of which, North America segment is expected to dominate the market over the forecast period, due to increasing inorganic growth strategies such as collaboration by key players in the region

Among all segmentation, application segment has the highest potential, due to increasing prevalence of cancer and this is expected to drive the global peptide therapeutics market over the forecast period. For instance, in May 2022, according to an article published by Springer Nature, a scientific journal, the projected cancer burden, in India, for 2021 was 26.7 million and is expected to increase to 29.8 million in 2025.

Global Peptide Therapeutics Market Cross Sectional Analysis:

In product type segment, branded peptide segment held a dominant position in North America region, due to increasing adoption of organic growth strategies such as product launches by key players in the market to expand their product portfolio. For instance, in June 2022, Vital Proteins a company that manufactures and retails health supplement products, announced the launch of Vital Proteins Lemon Collagen Peptide.

By route of administration, oral administration segment is expected to hold a dominant position over the forecast period, due to increasing use of peptide therapeutics technology for disease treatment. For instance, in July 2022, an article published by MDPI, a scientific journal, stated the use of oral peptide and protein-based drug liposomes and suggested that the combination of liposomes and other dosage forms to deliver drugs by oral route has shown more advantages with respect to the gastrointestinal stability.

Global Peptide Therapeutics Market: Key Developments

On August 5, 2021, Bayer AG, a Life Science company, announced the acquisition of Vividion Therapeutics, Inc., a U.S.-based biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics.

In December 2021, Sanofi, a global healthcare company, announced that it has entered into an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company, giving away its clinically validated product XTEN and innovative protease-releasable masking technology platform, Pro-XTENTM, to discover and develop transformative T-cell engagers (TCE) and cytokine therapies for patients with cancer.

In September 2022, the life science group Sartorius, through its subgroup Sartorius Stedim Biotech, successfully closed the acquisition of Albumedix Ltd, a world leading manufacturer of recombinant human albumin. This acquisition will enable Sartorius to strengthen their position as a relevant supplier of innovative chemically defined media and critical ancillary materials

In November 2022, Mesa Laboratories, Inc., a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, announced the acquisition of substantially all of the assets and certain liabilities related to Belyntic GmbH’s peptide purification business. Belyntic GmbH is a chemistry-for-healthcare enterprise focusing on purification of biopolymers, particularly peptides.

Due to the increasing product launches and company acquisition, it is expected that there will be new opportunities available for new startups which will drive the global peptide therapeutics market in the forecast period.

Global Peptide Therapeutics Market: Restraint

 Disadvantages of peptide therapeutics

The major factors that can hamper growth of the global peptide therapeutics market over the forecast period include false positive and negative responses, Major Histocompatibility Complex (MHC) restrictions, low immunogenic potency, and need for adjuvant such as such as aluminum hydroxide, aluminum phosphate, and aluminum potassium sulfate, etc. For instance, in March 2022, a report published by Springer Nature, a scientific journal, stated the major challenges of using peptide as targeted therapeutic agents, such as disproportionate physical and chemical properties, that must be changed to be in line with therapeutic goals and peptides limited affinity for cellular targets, which necessitates peptide structural alterations.

Global Peptide Therapeutics Market: Key Players

Major players operating in the global peptide therapeutics market include Teva Pharmaceutical Industries Ltd, Novo Nordisk A/S, OPKO Health, Inc., Lilly, Hanmi Pharm.Co., Sanofi, Circle Pharma, Pfizer Inc., Novartis AG, PeptiDream Inc., Amgen Inc., AstraZeneca, Bachem Holding AG, CordenPharma International, Ipsen Pharma, Merck KGaA, PolyPeptide Group, and Bayer AG.

Definition: Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) that are used for the treatment of diseases like cancer, diabetes, etc.